Table 18, Summary of included studies for inpatient versus outpatient subgroup analysis for comparison 3a Selective serotonin reuptake inhibitors (SSRIs) versus placebo - Service delivery Models and settings for delivery of services

Table 18Summary of included studies for inpatient versus outpatient subgroup analysis for comparison 3a Selective serotonin reuptake inhibitors (SSRIs) versus placebo

Study	Population	Intervention	Comparison	Comments
Inpatient setting (K=3, N=272)
29060 07 001^a RCT US	Inpatient N=25 Baseline severity: More severe Mean age (years): 42.5 Sex (% female): 56 Ethnicity (% BME): NR	Paroxetine 10-60mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
Katz 2004 RCT US	Inpatient N=53 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR	Paroxetine 20-60mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Sheehan 2009^b^a RCT US	Inpatient N=194 Baseline severity: More severe Mean age (years): 38.8 Sex (% female): 66 Ethnicity (% BME): NR	Fluoxetine 60-80mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Outpatient setting (K=74, N=16,736)
Baune 2018 RCT Estonia, Finland, Germany, & Lithuania	Outpatient N=104 Baseline severity: More severe Mean age (years): 45.7 Sex (% female): 64 Ethnicity (% BME): 2	Paroxetine 20mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
Binnemann 2008 RCT US, Serbia and Montenegro, & the Russian Federation	Outpatient N=82 Baseline severity: More severe Mean age (years): 49 Sex (% female): 39 Ethnicity (% BME): NR	Sertraline 100mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Bjerkenstedt 2005 RCT Sweden	Outpatient N=115 Baseline severity: More severe Mean age (years): 50.9 Sex (% female): 79 Ethnicity (% BME): 0	Fluoxetine 20mg/day	Placebo	Treatment duration (weeks): 4 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Blumenthal 2007/Hoffman 2011^b RCT US	Outpatient N=98 Baseline severity: More severe Mean age (years): 52 Sex (% female): 77 Ethnicity (% BME): 33	Sertraline 50-200mg/day	Placebo	Treatment duration (weeks): 16 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
Bose 2008 RCT US	Outpatient N=267 Baseline severity: More severe Mean age (years): 68.3 Sex (% female): 59 Ethnicity (% BME): 11	Escitalopram 10-20mg/day	Placebo	Treatment duration (weeks): 12 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Burke 2002 RCT US	Outpatient N=491 Baseline severity: More severe Mean age (years): 40.1 Sex (% female): 65 Ethnicity (% BME): NR	Escitalopram 10mg/day or 20mg/day, or citalopram 40mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Byerley 1988^a RCT US	Outpatient N=61 Baseline severity: More severe Mean age (years): 38.2 Sex (% female): 68 Ethnicity (% BME): NR	Fluoxetine 40-80mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Claghorn 1992^a RCT US	Outpatient N=59 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR	Paroxetine 10-50mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
Claghorn 1992^b RCT US	Outpatient N=72 Baseline severity: More severe Mean age (years): 35 Sex (% female): 32 Ethnicity (% BME): NR	Paroxetine 10-50mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Clayton 2006_study 1 RCT US	Outpatient N=283 Baseline severity: More severe Mean age (years): 35 Sex (% female): 61 Ethnicity (% BME): 35	Escitalopram 10-20mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Clayton 2006_study 2 RCT US	Outpatient N=286 Baseline severity: More severe Mean age (years): 36.5 Sex (% female): 56 Ethnicity (% BME): 27	Escitalopram 10-20mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Detke 2004^a RCT US	Outpatient N=179 Baseline severity: More severe Mean age (years): 42.9 Sex (% female): 71 Ethnicity (% BME): 0	Paroxetine 20mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Doogan 1994 RCT UK	Outpatient N=200 Baseline severity: More severe Mean age (years): 45.7 Sex (% female): 68 Ethnicity (% BME): NR	Sertraline 50-100mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Dube 2010 RCT India, US, Mexico & Romania	Outpatient N=200 Baseline severity: More severe Mean age (years): 36.5 Sex (% female): 44 Ethnicity (% BME): NR	Escitalopram 10-20mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Dunbar 1993 RCT US	Outpatient N=341 Baseline severity: More severe Mean age (years): 41 Sex (% female): 51 Ethnicity (% BME): NR	Paroxetine 10-50mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Eli Lilly HMAT-Aa RCT US	Outpatient N=179 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR	Paroxetine 20mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Emsley 2018 RCT Bulgaria, Estonia, Finland, France, Republic of Korea, Malaysia, Mexico, Poland, Romania, & Slovakia	Outpatient N=206 Baseline severity: More severe Mean age (years): 70.6 Sex (% female): 75 Ethnicity (% BME): NR	Escitalopram 10mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Fabre 1992^a RCT US	Outpatient N=80 Baseline severity: More severe Mean age (years): 35.8 Sex (% female): 59 Ethnicity (% BME): NR	Paroxetine 10-50mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
Fava 1998^a RCT US	Outpatient N=128 Baseline severity: More severe Mean age (years): 41.3 Sex (% female): 51 Ethnicity (% BME): NR	Paroxetine 20-50mg/day or fluoxetine 20-80mg/day	Placebo	Treatment duration (weeks): 12 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Fava 2005 RCT US	Outpatient N=90 Baseline severity: More severe Mean age (years): 37.2 Sex (% female): 59 Ethnicity (% BME): NR	Fluoxetine 20mg/day	Placebo	Treatment duration (weeks): 12 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
FDA 245 (EMD 68 843-010) RCT US	Outpatient N=191 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR	Fluoxetine 20mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
Forest Laboratories 2000 RCT US	Outpatient N=386 Baseline severity: More severe Mean age (years): 42 Sex (% female): 52 Ethnicity (% BME): NR	Escitalopram 10-20mg/day or citalopram 20-40mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Forest Research Institute 2005 RCT US	Outpatient N=409 Baseline severity: More severe Mean age (years): 40 Sex (% female): 56 Ethnicity (% BME): NR	Escitalopram 10-20mg/day or sertraline 50-200mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Golden 2002_448 RCT US	Outpatient N=315 Baseline severity: More severe Mean age (years): 39 Sex (% female): NR Ethnicity (% BME): NR	Paroxetine 20-62.5mg/day	Placebo	Treatment duration (weeks): 12 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
Golden 2002_449 RCT US	Outpatient N=330 Baseline severity: More severe Mean age (years): 41.2 Sex (% female): NR Ethnicity (% BME): NR	Paroxetine 20-62.5mg/day	Placebo	Treatment duration (weeks): 12 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
Goldstein 2002^a RCT US	Outpatient N=103 Baseline severity: More severe Mean age (years): 40.9 Sex (% female): 65 Ethnicity (% BME): 21	Fluoxetine 20mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Goldstein 2004^a RCT US	Outpatient N=176 Baseline severity: More severe Mean age (years): 40 Sex (% female): 64 Ethnicity (% BME): 22	Paroxetine 20mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Gual 2003 RCT Spain	Outpatient N=83 Baseline severity: More severe Mean age (years): 46.7 Sex (% female): 47 Ethnicity (% BME): NR	Sertraline 50-150mg/day	Placebo	Treatment duration (weeks): 24 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Hirayasu 2011^a RCT Japan	Outpatient N=310 34.6 Sex (% female): NR Ethnicity (% BME): NR	Escitalopram 10mg/day or 20mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Hirayasu 2011^b RCT Japan	Outpatient N=485 Baseline severity: More severe Mean age (years): 36.2 Sex (% female): NR Ethnicity (% BME): NR	Escitalopram 10mg/day or 20mg/day, or paroxetine 20-40mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Hunter 2010_study 1 RCT US	Outpatient N=28 Baseline severity: More severe Mean age (years): 42.4 Sex (% female): 68 Ethnicity (% BME): NR	Fluoxetine 20mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Hunter 2011 RCT US	Outpatient N=24 Baseline severity: More severe Mean age (years): 40.4 Sex (% female): 65 Ethnicity (% BME): NR	Fluoxetine 20mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Jefferson 2000 RCT US	Outpatient N=415 Baseline severity: More severe Mean age (years): 39.9 Sex (% female): NR Ethnicity (% BME): NR	Paroxetine 25mg/day, or citalopram 20mg/day or 40mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Keller 2006_Study 062 RCT Cross-continental	Outpatient N=325 Baseline severity: More severe Mean age (years): 41 Sex (% female): 67 Ethnicity (% BME): 43	Paroxetine 20mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
Komulainen 2018 RCT Finland	Outpatient N=37 Baseline severity: More severe Mean age (years): median 25.1 Sex (% female): 44 Ethnicity (% BME): NR	Escitalopram 10mg/day	Placebo	Treatment duration (weeks): 1 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
Kramer 1998 RCT US	Outpatient N=142 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR	Paroxetine 20mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Kranzler 2006_Group A RCT US	Outpatient N=189 Baseline severity: More severe Mean age (years): 42.9 Sex (% female): 35 Ethnicity (% BME): 10	Sertraline 50-200mg/day	Placebo	Treatment duration (weeks): 10 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Lam 2016^b RCT Canada	Outpatient N=61 Baseline severity: More severe Mean age (years): 36.8 Sex (% female): 72 Ethnicity (% BME): NR	Fluoxetine 20mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Lepola 2003 RCT Belgium, Canada, Finland, France, Norway, Sweden, Switzerland & UK	Outpatient N=469 Baseline severity: More severe Mean age (years): 43.3 Sex (% female): 72 Ethnicity (% BME): NR	Escitalopram 10-20mg/day or citalopram 20-40mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Macias-Cortes 2015 RCT Mexico	Outpatient N=89 Baseline severity: More severe Mean age (years): 49 Sex (% female): 100 Ethnicity (% BME): 100	Fluoxetine 20mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Mathews 2015 RCT US	Outpatient N=579 Baseline severity: More severe Mean age (years): 42.3 Sex (% female): 57 Ethnicity (% BME): 32	Citalopram 40mg/day	Placebo	Treatment duration (weeks): 10 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Mendels 1999 RCT US	Outpatient N=180 Baseline severity: More severe Mean age (years): 43 Sex (% female): 33 Ethnicity (% BME): 13	Citalopram 20-80mg/day	Placebo	Treatment duration (weeks): 4 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Miller 1989^a RCT UK	Outpatient N=47 Baseline severity: More severe Mean age (years): 42.5 Sex (% female): 68 Ethnicity (% BME): NR	Paroxetine 30mg/day	Placebo	Treatment duration (weeks): 4 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
Mundt 2012 RCT US	Outpatient N=165 Baseline severity: More severe Mean age (years): 37.8 Sex (% female): 63 Ethnicity (% BME): 24	Sertraline 50-100mg/day	Placebo	Treatment duration (weeks): 4 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
MY-1042/BRL-029060/CPMS-251 RCT US	Outpatient N=254 Baseline severity: More severe Mean age (years): 41.9 Sex (% female): NR Ethnicity (% BME): NR	Paroxetine 20-50mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
MY-1045/BRL-029060/1 (PAR 128) RCT US	Outpatient N=848 Baseline severity: More severe Mean age (years): 41.8 Sex (% female): NR Ethnicity (% BME): NR	Paroxetine 20-50mg/day or fluoxetine 20-80mg/day	Placebo	Treatment duration (weeks): 12 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Nemeroff 2007^a RCT US	Outpatient N=206 Baseline severity: More severe Mean age (years): 39.1 Sex (% female): 61 Ethnicity (% BME): 10	Fluoxetine 20-60mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Nierenberg 2007^a RCT US	Outpatient N=411 Baseline severity: More severe Mean age (years): 43 Sex (% female): 66 Ethnicity (% BME): 21	Escitalopram 10mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
NKD20006 (NCT00048204) RCT US	Outpatient N=250 Baseline severity: More severe Mean age (years): 38 Sex (% female): 60 Ethnicity (% BME): NR	Paroxetine 20mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Olie 1997 RCT France	Outpatient N=258 Baseline severity: More severe Mean age (years): 43.8 Sex (% female): 63 Ethnicity (% BME): 1	Sertraline 50-200mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Response
PAR 01 001 (GSK & FDA) RCT US	Outpatient N=50 Baseline severity: More severe Mean age (years): 43.1 Sex (% female): 35 Ethnicity (% BME): NR	Paroxetine 10-50mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Perahia 2006^a RCT Bulgaria, Croatia, Hungary, Poland, Romania, Russia, & Slovakia	Outpatient N=196 Baseline severity: More severe Mean age (years): 68.4 Sex (% female): 68 Ethnicity (% BME): 0	Paroxetine 20mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Peselow 1989a^a RCT US	Outpatient N=73 Baseline severity: More severe Mean age (years): 46.1 Sex (% female): 38 Ethnicity (% BME): NR	Paroxetine 10-50mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Peselow 1989b^a RCT US	Outpatient N=82 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR	Paroxetine 10-50mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Rapaport 2009 RCT US	Outpatient N=357 Baseline severity: More severe Mean age (years): 67.5 Sex (% female): 62 Ethnicity (% BME): 17	Paroxetine 25mg/day	Placebo	Treatment duration (weeks): 10 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Ratti 2011_study 096 RCT 11 countries in Europe and Latin America	Outpatient N=236 Baseline severity: More severe Mean age (years): 44 Sex (% female): 72 Ethnicity (% BME): NR	Paroxetine 20-30mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Ravindran 1995 RCT Canada	Outpatient N=66 Baseline severity: More severe Mean age (years): 38.9 Sex (% female): 62 Ethnicity (% BME): NR	Sertraline 50-200mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Reimherr 1990 RCT US & Canada	Outpatient N=299 Baseline severity: More severe Mean age (years): 39.6 Sex (% female): 53 Ethnicity (% BME): 8	Sertraline 20-200mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Rickels 1992 RCT US	Outpatient N=111 Baseline severity: More severe Mean age (years): 44.7 Sex (% female): 48 Ethnicity (% BME): NR	Paroxetine (dose NR)	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Roose 2004 RCT US	Outpatient N=178 Baseline severity: More severe Mean age (years): 79.6 Sex (% female): 58 Ethnicity (% BME): NR	Citalopram 20-40mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Rudolph 1999^a RCT US	Outpatient N=200 Baseline severity: More severe Mean age (years): 40 Sex (% female): 66 Ethnicity (% BME): NR	Fluoxetine 20-60mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Response
SER 315 (FDA)^a RCT Europe	Outpatient N=165 Baseline severity: More severe Mean age (years): 42.0 Sex (% female): 72 Ethnicity (% BME): NR	Sertraline 50-200mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
Smith 1992 RCT US	Outpatient N=77 Baseline severity: More severe Mean age (years): 44.8 Sex (% female): 50 Ethnicity (% BME): NR	Paroxetine 10-50mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Response
Stark 1985^a RCT US	Outpatient N=354 Baseline severity: More severe Mean age (years): 40.5 Sex (% female): 68 Ethnicity (% BME): NR	Fluoxetine 60-80mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Study 62b (FDA) RCT Country NR	Outpatient N=356 Baseline severity: More severe Mean age (years): 40 Sex (% female): 57 Ethnicity (% BME): NR	Fluoxetine 20mg/day, 40mg/day, or 60mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
Study F1J-MC-HMAQ – Study Group Ba RCT US	Outpatient N=112 Baseline severity: More severe Mean age (years): 40.8 Sex (% female): NR Ethnicity (% BME): NR	Fluoxetine 20mg/day	Placebo	Treatment duration (weeks): 10 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Tollefson 1993/1995 RCT US	Outpatient N=671 Baseline severity: More severe Mean age (years): 67.7 Sex (% female): 55 Ethnicity (% BME): 6	Fluoxetine maximum 20mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Valle-Cabrera 2018 RCT Cuba	Outpatient N=77 Baseline severity: More severe Mean age (years): 45.2 Sex (% female): 92 Ethnicity (% BME): NR	Sertraline 50-200mg/day	Placebo	Treatment duration (weeks): 10 Outcomes (for inpatient versus outpatient subgroup analysis): Response
VEN XR 367 (FDA)^a RCT Europe	Outpatient N=164 Baseline severity: More severe Mean age (years): NR Sex (% female): 61 Ethnicity (% BME): NR	Paroxetine 20mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
Wade 2002 RCT Canada, Estonia, France, Netherlands & UK	Outpatient N=380 Baseline severity: More severe Mean age (years): 40.5 Sex (% female): 76 Ethnicity (% BME): 3	Escitalopram 10mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Wang 2014c RCT Canada, China, Finland, South Korea, Malaysia, Mexico, The Philippines, South Africa, & Spain	Outpatient N=314 Baseline severity: More severe Mean age (years): 40 Sex (% female): 71 Ethnicity (% BME): 46	Escitalopram 10-20mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Response
WELL AK1A4006 RCT US	Outpatient N=309 Baseline severity: More severe Mean age (years): 37.9 Sex (% female): NR Ethnicity (% BME): NR	Fluoxetine 20-60mg/day	Placebo	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Wernicke 1987 RCT US	Outpatient N=356 Baseline severity: More severe Mean age (years): 39.8 Sex (% female): 57 Ethnicity (% BME): NR	Fluoxetine 20mg/day, 40mg/day, or 60mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response
Wernicke 1988 RCT US	Outpatient N=267 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR	Fluoxetine 20mg/day or 40mg/day	Placebo	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Response

Study

Population

Intervention

Comparison

Comments

Inpatient setting (K=3, N=272)

29060 07 001^a

RCT

Inpatient

N=25

Baseline severity: More severe

Mean age (years): 42.5

Sex (% female): 56

Ethnicity (% BME): NR

Paroxetine 10-60mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

Katz 2004

RCT

Inpatient

N=53

Baseline severity: More severe

Mean age (years): NR

Sex (% female): NR

Ethnicity (% BME): NR

Paroxetine 20-60mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Sheehan 2009^b^a

RCT

Inpatient

N=194

Baseline severity: More severe

Mean age (years): 38.8

Sex (% female): 66

Ethnicity (% BME): NR

Fluoxetine 60-80mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Outpatient setting (K=74, N=16,736)

Baune 2018

RCT

Estonia, Finland, Germany, & Lithuania

Outpatient

N=104

Baseline severity: More severe

Mean age (years): 45.7

Sex (% female): 64

Ethnicity (% BME): 2

Paroxetine 20mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

Binnemann 2008

RCT

US, Serbia and Montenegro, & the Russian Federation

Outpatient

N=82

Baseline severity: More severe

Mean age (years): 49

Sex (% female): 39

Ethnicity (% BME): NR

Sertraline 100mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Bjerkenstedt 2005

RCT

Sweden

Outpatient

N=115

Baseline severity: More severe

Mean age (years): 50.9

Sex (% female): 79

Ethnicity (% BME): 0

Fluoxetine 20mg/day

Placebo

Treatment duration (weeks): 4

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Blumenthal 2007/Hoffman 2011^b

RCT

Outpatient

N=98

Baseline severity: More severe

Mean age (years): 52

Sex (% female): 77

Ethnicity (% BME): 33

Sertraline 50-200mg/day

Placebo

Treatment duration (weeks): 16

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

Bose 2008

RCT

Outpatient

N=267

Baseline severity: More severe

Mean age (years): 68.3

Sex (% female): 59

Ethnicity (% BME): 11

Escitalopram 10-20mg/day

Placebo

Treatment duration (weeks): 12

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Burke 2002

RCT

Outpatient

N=491

Baseline severity: More severe

Mean age (years): 40.1

Sex (% female): 65

Ethnicity (% BME): NR

Escitalopram 10mg/day or 20mg/day, or citalopram 40mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Byerley 1988^a

RCT

Outpatient

N=61

Baseline severity: More severe

Mean age (years): 38.2

Sex (% female): 68

Ethnicity (% BME): NR

Fluoxetine 40-80mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Claghorn 1992^a

RCT

Outpatient

N=59

Baseline severity: More severe

Mean age (years): NR

Sex (% female): NR

Ethnicity (% BME): NR

Paroxetine 10-50mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

Claghorn 1992^b

RCT

Outpatient

N=72

Baseline severity: More severe

Mean age (years): 35

Sex (% female): 32

Ethnicity (% BME): NR

Paroxetine 10-50mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Clayton 2006_study 1

RCT

Outpatient

N=283

Baseline severity: More severe

Mean age (years): 35

Sex (% female): 61

Ethnicity (% BME): 35

Escitalopram 10-20mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Clayton 2006_study 2

RCT

Outpatient

N=286

Baseline severity: More severe

Mean age (years): 36.5

Sex (% female): 56

Ethnicity (% BME): 27

Escitalopram 10-20mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Detke 2004^a

RCT

Outpatient

N=179

Baseline severity: More severe

Mean age (years): 42.9

Sex (% female): 71

Ethnicity (% BME): 0

Paroxetine 20mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Doogan 1994

RCT

Outpatient

N=200

Baseline severity: More severe

Mean age (years): 45.7

Sex (% female): 68

Ethnicity (% BME): NR

Sertraline 50-100mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Dube 2010

RCT

India, US, Mexico & Romania

Outpatient

N=200

Baseline severity: More severe

Mean age (years): 36.5

Sex (% female): 44

Ethnicity (% BME): NR

Escitalopram 10-20mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Dunbar 1993

RCT

Outpatient

N=341

Baseline severity: More severe

Mean age (years): 41

Sex (% female): 51

Ethnicity (% BME): NR

Paroxetine 10-50mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Eli Lilly HMAT-Aa

RCT

Outpatient

N=179

Baseline severity: More severe

Mean age (years): NR

Sex (% female): NR

Ethnicity (% BME): NR

Paroxetine 20mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Emsley 2018

RCT

Bulgaria, Estonia, Finland, France, Republic of Korea, Malaysia, Mexico, Poland, Romania, & Slovakia

Outpatient

N=206

Baseline severity: More severe

Mean age (years): 70.6

Sex (% female): 75

Ethnicity (% BME): NR

Escitalopram 10mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Fabre 1992^a

RCT

Outpatient

N=80

Baseline severity: More severe

Mean age (years): 35.8

Sex (% female): 59

Ethnicity (% BME): NR

Paroxetine 10-50mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

Fava 1998^a

RCT

Outpatient

N=128

Baseline severity: More severe

Mean age (years): 41.3

Sex (% female): 51

Ethnicity (% BME): NR

Paroxetine 20-50mg/day or fluoxetine 20-80mg/day

Placebo

Treatment duration (weeks): 12

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

Response

Fava 2005

RCT

Outpatient

N=90

Baseline severity: More severe

Mean age (years): 37.2

Sex (% female): 59

Ethnicity (% BME): NR

Fluoxetine 20mg/day

Placebo

Treatment duration (weeks): 12

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

FDA 245 (EMD 68 843-010)

RCT

Outpatient

N=191

Baseline severity: More severe

Mean age (years): NR

Sex (% female): NR

Ethnicity (% BME): NR

Fluoxetine 20mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

Forest Laboratories 2000

RCT

Outpatient

N=386

Baseline severity: More severe

Mean age (years): 42

Sex (% female): 52

Ethnicity (% BME): NR

Escitalopram 10-20mg/day or citalopram 20-40mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Forest Research Institute 2005

RCT

Outpatient

N=409

Baseline severity: More severe

Mean age (years): 40

Sex (% female): 56

Ethnicity (% BME): NR

Escitalopram 10-20mg/day or sertraline 50-200mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Golden 2002_448

RCT

Outpatient

N=315

Baseline severity: More severe

Mean age (years): 39

Sex (% female): NR

Ethnicity (% BME): NR

Paroxetine 20-62.5mg/day

Placebo

Treatment duration (weeks): 12

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

Golden 2002_449

RCT

Outpatient

N=330

Baseline severity: More severe

Mean age (years): 41.2

Sex (% female): NR

Ethnicity (% BME): NR

Paroxetine 20-62.5mg/day

Placebo

Treatment duration (weeks): 12

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

Goldstein 2002^a

RCT

Outpatient

N=103

Baseline severity: More severe

Mean age (years): 40.9

Sex (% female): 65

Ethnicity (% BME): 21

Fluoxetine 20mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Goldstein 2004^a

RCT

Outpatient

N=176

Baseline severity: More severe

Mean age (years): 40

Sex (% female): 64

Ethnicity (% BME): 22

Paroxetine 20mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Gual 2003

RCT

Spain

Outpatient

N=83

Baseline severity: More severe

Mean age (years): 46.7

Sex (% female): 47

Ethnicity (% BME): NR

Sertraline 50-150mg/day

Placebo

Treatment duration (weeks): 24

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Hirayasu 2011^a

RCT

Japan

Outpatient

N=310

34.6

Sex (% female): NR

Ethnicity (% BME): NR

Escitalopram 10mg/day or 20mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Hirayasu 2011^b

RCT

Japan

Outpatient

N=485

Baseline severity: More severe

Mean age (years): 36.2

Sex (% female): NR

Ethnicity (% BME): NR

Escitalopram 10mg/day or 20mg/day, or paroxetine 20-40mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Hunter 2010_study 1

RCT

Outpatient

N=28

Baseline severity: More severe

Mean age (years): 42.4

Sex (% female): 68

Ethnicity (% BME): NR

Fluoxetine 20mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Hunter 2011

RCT

Outpatient

N=24

Baseline severity: More severe

Mean age (years): 40.4

Sex (% female): 65

Ethnicity (% BME): NR

Fluoxetine 20mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Jefferson 2000

RCT

Outpatient

N=415

Baseline severity: More severe

Mean age (years): 39.9

Sex (% female): NR

Ethnicity (% BME): NR

Paroxetine 25mg/day, or citalopram 20mg/day or 40mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Keller 2006_Study 062

RCT

Cross-continental

Outpatient

N=325

Baseline severity: More severe

Mean age (years): 41

Sex (% female): 67

Ethnicity (% BME): 43

Paroxetine 20mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

Komulainen 2018

RCT

Finland

Outpatient

N=37

Baseline severity: More severe

Mean age (years): median 25.1

Sex (% female): 44

Ethnicity (% BME): NR

Escitalopram 10mg/day

Placebo

Treatment duration (weeks): 1

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

Kramer 1998

RCT

Outpatient

N=142

Baseline severity: More severe

Mean age (years): NR

Sex (% female): NR

Ethnicity (% BME): NR

Paroxetine 20mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Kranzler 2006_Group A

RCT

Outpatient

N=189

Baseline severity: More severe

Mean age (years): 42.9

Sex (% female): 35

Ethnicity (% BME): 10

Sertraline 50-200mg/day

Placebo

Treatment duration (weeks): 10

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Lam 2016^b

RCT

Canada

Outpatient

N=61

Baseline severity: More severe

Mean age (years): 36.8

Sex (% female): 72

Ethnicity (% BME): NR

Fluoxetine 20mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Lepola 2003

RCT

Belgium, Canada, Finland, France, Norway, Sweden, Switzerland & UK

Outpatient

N=469

Baseline severity: More severe

Mean age (years): 43.3

Sex (% female): 72

Ethnicity (% BME): NR

Escitalopram 10-20mg/day or citalopram 20-40mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Macias-Cortes 2015

RCT

Mexico

Outpatient

N=89

Baseline severity: More severe

Mean age (years): 49

Sex (% female): 100

Ethnicity (% BME): 100

Fluoxetine 20mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Mathews 2015

RCT

Outpatient

N=579

Baseline severity: More severe

Mean age (years): 42.3

Sex (% female): 57

Ethnicity (% BME): 32

Citalopram 40mg/day

Placebo

Treatment duration (weeks): 10

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Mendels 1999

RCT

Outpatient

N=180

Baseline severity: More severe

Mean age (years): 43

Sex (% female): 33

Ethnicity (% BME): 13

Citalopram 20-80mg/day

Placebo

Treatment duration (weeks): 4

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Miller 1989^a

RCT

Outpatient

N=47

Baseline severity: More severe

Mean age (years): 42.5

Sex (% female): 68

Ethnicity (% BME): NR

Paroxetine 30mg/day

Placebo

Treatment duration (weeks): 4

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

Mundt 2012

RCT

Outpatient

N=165

Baseline severity: More severe

Mean age (years): 37.8

Sex (% female): 63

Ethnicity (% BME): 24

Sertraline 50-100mg/day

Placebo

Treatment duration (weeks): 4

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

MY-1042/BRL-029060/CPMS-251

RCT

Outpatient

N=254

Baseline severity: More severe

Mean age (years): 41.9

Sex (% female): NR

Ethnicity (% BME): NR

Paroxetine 20-50mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

MY-1045/BRL-029060/1 (PAR 128)

RCT

Outpatient

N=848

Baseline severity: More severe

Mean age (years): 41.8

Sex (% female): NR

Ethnicity (% BME): NR

Paroxetine 20-50mg/day or fluoxetine 20-80mg/day

Placebo

Treatment duration (weeks): 12

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Nemeroff 2007^a

RCT

Outpatient

N=206

Baseline severity: More severe

Mean age (years): 39.1

Sex (% female): 61

Ethnicity (% BME): 10

Fluoxetine 20-60mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Nierenberg 2007^a

RCT

Outpatient

N=411

Baseline severity: More severe

Mean age (years): 43

Sex (% female): 66

Ethnicity (% BME): 21

Escitalopram 10mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

NKD20006 (NCT00048204)

RCT

Outpatient

N=250

Baseline severity: More severe

Mean age (years): 38

Sex (% female): 60

Ethnicity (% BME): NR

Paroxetine 20mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Olie 1997

RCT

France

Outpatient

N=258

Baseline severity: More severe

Mean age (years): 43.8

Sex (% female): 63

Ethnicity (% BME): 1

Sertraline 50-200mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

PAR 01 001 (GSK & FDA)

RCT

Outpatient

N=50

Baseline severity: More severe

Mean age (years): 43.1

Sex (% female): 35

Ethnicity (% BME): NR

Paroxetine 10-50mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

Response

Perahia 2006^a

RCT

Bulgaria, Croatia, Hungary, Poland, Romania, Russia, & Slovakia

Outpatient

N=196

Baseline severity: More severe

Mean age (years): 68.4

Sex (% female): 68

Ethnicity (% BME): 0

Paroxetine 20mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Peselow 1989a^a

RCT

Outpatient

N=73

Baseline severity: More severe

Mean age (years): 46.1

Sex (% female): 38

Ethnicity (% BME): NR

Paroxetine 10-50mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Peselow 1989b^a

RCT

Outpatient

N=82

Baseline severity: More severe

Mean age (years): NR

Sex (% female): NR

Ethnicity (% BME): NR

Paroxetine 10-50mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Rapaport 2009

RCT

Outpatient

N=357

Baseline severity: More severe

Mean age (years): 67.5

Sex (% female): 62

Ethnicity (% BME): 17

Paroxetine 25mg/day

Placebo

Treatment duration (weeks): 10

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Ratti 2011_study 096

RCT

11 countries in Europe and Latin America

Outpatient

N=236

Baseline severity: More severe

Mean age (years): 44

Sex (% female): 72

Ethnicity (% BME): NR

Paroxetine 20-30mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Ravindran 1995

RCT

Canada

Outpatient

N=66

Baseline severity: More severe

Mean age (years): 38.9

Sex (% female): 62

Ethnicity (% BME): NR

Sertraline 50-200mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Reimherr 1990

RCT

US & Canada

Outpatient

N=299

Baseline severity: More severe

Mean age (years): 39.6

Sex (% female): 53

Ethnicity (% BME): 8

Sertraline 20-200mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Rickels 1992

RCT

Outpatient

N=111

Baseline severity: More severe

Mean age (years): 44.7

Sex (% female): 48

Ethnicity (% BME): NR

Paroxetine (dose NR)

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Roose 2004

RCT

Outpatient

N=178

Baseline severity: More severe

Mean age (years): 79.6

Sex (% female): 58

Ethnicity (% BME): NR

Citalopram 20-40mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Rudolph 1999^a

RCT

Outpatient

N=200

Baseline severity: More severe

Mean age (years): 40

Sex (% female): 66

Ethnicity (% BME): NR

Fluoxetine 20-60mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

SER 315 (FDA)^a

RCT

Europe

Outpatient

N=165

Baseline severity: More severe

Mean age (years): 42.0

Sex (% female): 72

Ethnicity (% BME): NR

Sertraline 50-200mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

Smith 1992

RCT

Outpatient

N=77

Baseline severity: More severe

Mean age (years): 44.8

Sex (% female): 50

Ethnicity (% BME): NR

Paroxetine 10-50mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

Stark 1985^a

RCT

Outpatient

N=354

Baseline severity: More severe

Mean age (years): 40.5

Sex (% female): 68

Ethnicity (% BME): NR

Fluoxetine 60-80mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Study 62b (FDA)

RCT

Country NR

Outpatient

N=356

Baseline severity: More severe

Mean age (years): 40

Sex (% female): 57

Ethnicity (% BME): NR

Fluoxetine 20mg/day, 40mg/day, or 60mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

Study F1J-MC-HMAQ – Study Group Ba

RCT

Outpatient

N=112

Baseline severity: More severe

Mean age (years): 40.8

Sex (% female): NR

Ethnicity (% BME): NR

Fluoxetine 20mg/day

Placebo

Treatment duration (weeks): 10

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Tollefson 1993/1995

RCT

Outpatient

N=671

Baseline severity: More severe

Mean age (years): 67.7

Sex (% female): 55

Ethnicity (% BME): 6

Fluoxetine maximum 20mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Valle-Cabrera 2018

RCT

Cuba

Outpatient

N=77

Baseline severity: More severe

Mean age (years): 45.2

Sex (% female): 92

Ethnicity (% BME): NR

Sertraline 50-200mg/day

Placebo

Treatment duration (weeks): 10

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

VEN XR 367 (FDA)^a

RCT

Europe

Outpatient

N=164

Baseline severity: More severe

Mean age (years): NR

Sex (% female): 61

Ethnicity (% BME): NR

Paroxetine 20mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

Wade 2002

RCT

Canada, Estonia, France, Netherlands & UK

Outpatient

N=380

Baseline severity: More severe

Mean age (years): 40.5

Sex (% female): 76

Ethnicity (% BME): 3

Escitalopram 10mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Wang 2014c

RCT

Canada, China, Finland, South Korea, Malaysia, Mexico, The Philippines, South Africa, & Spain

Outpatient

N=314

Baseline severity: More severe

Mean age (years): 40

Sex (% female): 71

Ethnicity (% BME): 46

Escitalopram 10-20mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Response

WELL AK1A4006

RCT

Outpatient

N=309

Baseline severity: More severe

Mean age (years): 37.9

Sex (% female): NR

Ethnicity (% BME): NR

Fluoxetine 20-60mg/day

Placebo

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Wernicke 1987

RCT

Outpatient

N=356

Baseline severity: More severe

Mean age (years): 39.8

Sex (% female): 57

Ethnicity (% BME): NR

Fluoxetine 20mg/day, 40mg/day, or 60mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

Wernicke 1988

RCT

Outpatient

N=267

Baseline severity: More severe

Mean age (years): NR

Sex (% female): NR

Ethnicity (% BME): NR

Fluoxetine 20mg/day or 40mg/day

Placebo

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Response

a: Three-armed trial but where possible the demographics reported here are for only the two relevant arms.
b: Four-armed trial but where possible the demographics reported here are for only the two relevant arms
: BME: black, minority, ethnic; mg: milligrams; N: number of participants; NR: not reported; RCT: randomised controlled trial.

From: Service delivery Models and settings for delivery of services

Cover of Service delivery Models and settings for delivery of services

Service delivery Models and settings for delivery of services: Depression in adults: Evidence review A.

NICE Guideline, No. 222.

London: National Institute for Health and Care Excellence (NICE); 2022 Jun.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.